156 related articles for article (PubMed ID: 16497087)
1. Miotic action of tramadol is determined by CYP2D6 genotype.
Slanar O; Nobilis M; Kvetina J; Mikoviny R; Zima T; Idle JR; Perlík F
Physiol Res; 2007; 56(1):129-136. PubMed ID: 16497087
[TBL] [Abstract][Full Text] [Related]
2. A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol.
Borlak J; Hermann R; Erb K; Thum T
Metabolism; 2003 Nov; 52(11):1439-43. PubMed ID: 14624403
[TBL] [Abstract][Full Text] [Related]
3. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
4. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
6. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
7. Pupillometry in healthy volunteers as a biomarker of tramadol efficacy.
Matouskova O; Slanar O; Chytil L; Perlik F
J Clin Pharm Ther; 2011 Aug; 36(4):513-7. PubMed ID: 21729116
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain.
Noehr-Jensen L; Zwisler ST; Larsen F; Sindrup SH; Damkier P; Brosen K
Clin Pharmacol Ther; 2009 Dec; 86(6):626-33. PubMed ID: 19710642
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W
Mol Diagn Ther; 2007; 11(3):171-81. PubMed ID: 17570739
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
Pedersen RS; Damkier P; Brøsen K
Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
[TBL] [Abstract][Full Text] [Related]
11. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
Abdel-Rahman SM; Leeder JS; Wilson JT; Gaedigk A; Gotschall RR; Medve R; Liao S; Spielberg SP; Kearns GL
J Clin Pharmacol; 2002 Jan; 42(1):24-9. PubMed ID: 11808821
[TBL] [Abstract][Full Text] [Related]
12. The hypoalgesic effect of tramadol in relation to CYP2D6.
Poulsen L; Arendt-Nielsen L; Brøsen K; Sindrup SH
Clin Pharmacol Ther; 1996 Dec; 60(6):636-44. PubMed ID: 8988065
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response.
Slanar O; Nobilis M; Kvetina J; Idle JR; Perlík F
Eur J Clin Pharmacol; 2006 Jan; 62(1):75-6; author reply 77-8. PubMed ID: 16283276
[No Abstract] [Full Text] [Related]
14. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
15. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
17. Differential Consequences of Tramadol in Overdosing: Dilemma of a Polymorphic Cytochrome P450 2D6-Mediated Substrate.
Srinivas NR
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):272-5. PubMed ID: 26367475
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.
Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K
Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129
[TBL] [Abstract][Full Text] [Related]
20. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
